Tenecteplase

RESEARCH TRIANGLE, N.C., July 30, 2026 /PRNewswire/ -- Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a first-in-class, targeted, reversible thrombolytic therapy for acute ischemic stroke (AIS), today announced the publication of preclinical research in Communications Biology, a Nature Portfolio journal. The study shows that its lead candidate, BB-031, restores blood flow in a microfluidic model of arterial occlusion using blood samples from AIS patients by selectively inhibiting von Willebrand Factor (vWF), a key mediator of clot initiation, growth and stabilization. The research was led by scientists at the University of Pittsburgh and The Ohio State University. The study evaluated how BB-031 reopens vessels and compared its performance with the two approved fibrinolytics, alteplase (tPA) and tenecteplase (TNK). In the model, fully occlusive, platelet-rich clots were formed under arterial flow conditions, allowed to mature for up to six hours, and then treated. Results showed that BB-031 restored blood flow through occluded channels more effectively than both alteplase and tenecteplase, including clots that had matured for three to six hours. BB-031 also worked by preventing vWF from recruiting new platelets to the clot surface, a process that continually reinforces platelet-rich arterial clots and makes them resistant to current fibrinolytics. "The model allowed us to see what may be happening to arterial clots in prolonged settings, providing a closer analog to clinical reality. This advance allowed us to better interrogate the potential advantages of a vWF-targeting strategy, complementing our earlier studies," said Susan M. Shea, M.S.M.E., Ph.D., Assistant Professor in the Trauma and Transfusion Medicine Research Center, Department of Surgery at the University of Pittsburgh and senior author on the study. Blood samples from AIS patients showed restored blood flow with BB-031 compared with the vehicle. Importantly, clots formed in the model reproduced the clot composition reported in human samples from patients who have undergone endovascular thrombectomy (EVT). These include fibrin, platelets, and vWF, supporting the model as a relevant system for studying arterial thrombosis and treatment. "These findings show that BB-031 restores blood flow in an occlusive thrombus after a clot has already formed and matured," said Shahid M. Nimjee, M.D., Ph.D., co-founder, chief scientific officer and stroke clinical lead of Basking Biosciences. "Von Willebrand Factor continually recruits platelets that reinforce arterial clots, thereby engendering resistance to current therapies. By selectively inhibiting vWF, BB-031 stops that reinforcement and allows blood flow to return, even when treatment is administered hours after the occlusion forms. This gives us clear insight into how BB-031 works in human clot formation and strengthens the rationale for our clinical program in acute ischemic stroke." Stroke remains one of the leading causes of death and disability worldwide. Fibrinolytics, the pharmacological standard of care since 1996, are limited by a narrow 3- to 4.5-hour treatment window and a serious bleeding risk. Mechanical thrombectomy, adopted globally in 2015, can extend treatment up to 24 hours, but it is available only in specialized centers. Current literature supports limiting it to patients who present with large vessel occlusion stroke. BB-031 offers a different approach. It selectively and reversibly inhibits vWF and can be paired with BB-025, a direct-acting reversal agent designed to rapidly restore normal hemostasis within minutes, if needed, enabling potential urgent surgical intervention in the event of bleeding. "This publication adds important mechanistic evidence to our program, and it is encouraging to see our approach validated in blood samples from stroke patients," said Julia C. Owens, Ph.D., chief executive officer of Basking Biosciences. "Findings like these strengthen our conviction as we advance BB-031 through our Phase 2 RAISE trial and work toward a treatment that could reach many stroke patients who do not currently receive acute treatment." The Phase 2 RAISE trial is a multicenter, randomized, double-blind, dose-finding study evaluating BB-031 versus placebo in patients with AIS who present within 24 hours of symptom onset. The trial includes two parts. Part A was completed in 2025. Part B will enroll approximately 180 patients. The trial is being conducted at sites across North America and Australia, with additional site activation planned. The full manuscript, titled "Von Willebrand factor A1 blockade prevents platelet-mediated sustained occlusion for the treatment of arterial thrombosis," is available at About BB-031 BB-031 is an investigational RNA aptamer designed to selectively inhibit von Willebrand Factor (vWF), a central mediator of clot initiation, growth and stabilization. By targeting vWF with high affinity and selectivity, BB-031 is intended to enable potent inhibition of this key element of clot stabilization, resulting in rapid restoration of blood flow that could extend the treatment window and broaden treatment opportunities for patients with acute ischemic stroke (AIS). In the event of bleeding or the need for urgent surgical intervention, BB-025 can be administered to neutralize BB-031. About BB-025 BB-025 is an investigational, rapid-acting oligonucleotide reversal agent that specifically binds to BB-031. Administered as a single intravenous bolus, BB-025 is designed to rapidly and durably reverse BB-031's thrombolytic activity. By delivering immediate, durable neutralization of BB-031, BB-025 is being developed to provide clinicians with a built-in safety mechanism that can reverse BB-031's thrombolytic activity in the event of bleeding or the need for urgent surgical intervention. About Acute Ischemic Stroke Acute Ischemic Stroke (AIS) is the leading cause of combined mortality and morbidity worldwide, accounting for 87 percent of all strokes. According to the World Health Organization, 15 million people suffer a stroke each year, resulting in more than 5 million deaths. Currently available therapies, including intravenous thrombolytics and mechanical thrombectomy, reach no more than 20 percent of patients, even in the best stroke centers. About Basking Biosciences Basking Biosciences is a clinical-stage biopharmaceutical company dedicated to changing the way potentially life-threatening blood clots are treated. Its novel therapies are designed to significantly improve safety and efficacy, broadening access to many more patients. The company's lead candidate, BB-031, is the first rapid-onset, short-acting thrombolytic therapy with a direct-acting reversal agent, currently in development for the treatment of acute ischemic stroke. By selectively inhibiting von Willebrand Factor (vWF), a central mediator of clot initiation, growth, and stabilization, BB-031 delivers potent, targeted thrombolytic activity that, together with its reversal agent BB-025, could enable more patients to receive timely, life-saving treatment after stroke. For more information, visit and follow us on LinkedIn. SOURCE Basking Biosciences Inc. 21% more press release views with Request a Demo

药企医学部制作药物临床对比市场材料，是连接研发成果与商业价值的关键桥梁。这一过程不仅关乎学术推广的合规与专业，更直接影响药品的市场准入及商业化前景。 一、 制作临床对比材料的核心路径 医学部在制作此类材料时，通常需要遵循严谨的科学逻辑与合规流程，主要路径包括以下几个关键环节： 1. 深度调研与竞品摸底 制作对比材料的第一步是“摸清家底”。医学部需要全面收集目标适应症下的竞品数据，包括查阅国内权威指南、药监局官网信息、已发表的最新文献综述（Review）以及临床试验进度等2。同时，需梳理竞品在机制、剂型、用量、药代动力学、获批适应症以及关键三期研究终点（如疗效和安全性数据）等方面的核心信息24。 2. 确立科学的对照药（参照药）标准 选择正确的对照药物是临床对比的灵魂。医学部需明确，药监体系的参照药（如一致性评价的参比制剂）与医保体系的参照药（药物有效性与安全性方面）存在差异。在对比时，应优先锚定医保支付范围内、临床应用最广泛且同治疗领域的现有品种，避免盲目选择最新、最贵的药物以操纵溢价，或误用安慰剂作为价值参照。 3. 构建多维度的综合评价体系 现代药品的临床对比早已超越了单一的疗效比拼，而是基于循证医学证据进行多维度整合分析。医学部需围绕六大核心维度展开评估：临床有效性、临床安全性、临床适用性、可及性以及社会价值。 4. 严谨的医学写作与合规质控 在材料撰写阶段，医学写作团队需对靶点、疾病领域及试验设计有深入理解。必须确保引用的文献数据准确标注出处，严禁夹带未经证实的主观营销表述（如“显著优于”、“远超竞品”等）。所有输出内容需经过严格的合规审核，确保符合相关质量管理规范，做到全流程留痕可追溯。 5. 提炼核心价值主张（VCP）与差异化定位 基于详实的临床数据对比，医学部能够提炼出新药独特的、具有说服力的核心价值主张，清晰回答“为什么医生和患者应该选择这款药”4。这有助于新药在激烈的市场竞争中形成差异化形象，精准确立其在治疗体系中的地位（如一线、二线或联合用药）。 6. 赋能一线学术推广与KOL沟通 结构化的临床对比材料（如临床数据手册、医学概要等）为医学联络官（MSL）和市场团队提供了坚实的学术弹药。通过数字化医学内容库和智能问答系统，医学部能高效、精准地向临床医生传递跨适应症的用药证据链，支持KOL的培养与高水平学术活动的开展。 二、药物临床对比材料的制作 传统的药物临床对比，需要检索大量的文献及临床试验结论。需要MSL或医学经理花费大量时间进行资料整理，同时对于不同临床试验需要分组剂型对比。 对于临床试验的总体维度遵循： 试验设计 基线 有效性 安全性 按照这样的对比维度，我们可以完成临床试验科学数据的比较。 但是并不是所有临床试验都能直接拿来比较，我们需要区分一下几类试验设计。 第一优先：头对头（最高级别证据）,目标药物与阳性药物直接临床证据 第二优先：一线对照，目标药物与一线疗法的临床试验，对比阳性药物与一线疗法的临床试验 第三优先：后线单药单臂，目标药物与阳性药物，均存在后线的单药临床试验 第四优先：安慰剂对照，目标药物与阳性药物，各自的安慰剂对照试验进行临床对比 我们必须要对临床试验进行分组，才能够合理的评价出药物疗效不良反应之间的差异。 我们以现在市场上比较火的双抗药物依沃西单抗与K药物的临床对比分析为例，使用药番茄临床对比工具。可以自动对临床试验进行分组，以确定相同的临床试验设计进行对比。 依沃西单抗 VS 帕博丽珠单抗（非小细胞肺癌，以三期临床作为主要评估） 对于不同的分组，药番茄临床对比平台可以直接列出对比表格，极大的方便MA同事的工作量。 最后所有对比内容均有完整的数据支持与结论，帮助医学部同事形成完善的学术营销资料。 对于肿瘤药物而言，新药不断，可以使用药番茄临床对比平台直接获取药物临床对比分析报告，每个内容都有严肃的数据源作为循证。 对于溶栓药物美通立与明复乐，一直是2大直接对标的产品，一个石药集团产品，另一个为勃林格殷格翰产品，两者在药物市场上形成了明确的竞对。 美通立 VS 明复乐（急性缺血卒中，以三期临床作为主要评估） 对于基线、有效性、安全性分析，可以直接通过药番茄平台直接得出结论。 疗效要点：美通立提供了可引用的精确主终点率与非劣效统计量；明复乐提供了 Lancet 级 TRACE-2 非劣效确证与国产 AIS 适应症注册路径。二者均未显示需改写“可替代阿替普酶”定位的劣效信号。 不良反应要点： 关键关注的 sICH、严重出血与死亡在 0.25 mg/kg AIS 公开结论层未显示相对阿替普酶的系统性恶化；高剂量卒中路径与 PE 全剂量溶栓标出出血上限，应用于外推边界，而非主场景下的商品名排名。 局限性：主结论来自间接比较而非两药直接随机；人群 EVT 排除条款、基线与部分安全分项披露不完整；桥接、超窗、STEMI、PE 等无法在本报告内完成美通立 vs 明复乐的配对读出。 前瞻：后续应跟踪双方桥接/取栓相关 III 期结果、补齐 TRACE-2 与 ORIGINAL 的完整终点与基线表，并在有真正策略对齐数据时再考虑扩展第二主对比组。在现有证据下，不宜宣称某一制剂在溶栓疗效或不良反应上整体优于另一制剂；实践分化应更多结合可及性、供应与流程落地综合判断。 你只需要给出需要对比的药物，和目标适应症，剩下的内容就全部交给药番茄好了，10分钟后回来下载你的临床对比报告。 想获得上述（美通立 VS 明复乐；依沃西单抗 VS K药）的完整报告，或使用药番茄临床对比，欢迎注册pharmato.cn，并联系助理。 --- 以上正文 --- 往期好文 从600万化合物到4个月育种——拜耳AI研发全景的技术拆解与数据验证 MRD降至44%、0例CRS：IMUNON公布IMNN-001卵巢癌II期数据 药番茄：多智能体医药AI计算平台，药企口中真正的好产品 从一个临床问题到一份专业预测报告：药番茄深度探索如何助力创新药临床分析 最高38亿美元！礼来（Eli Lilly）收购 AtaiBeckley，押注精神疾病赛道 一句话生成IgAN竞争情报分析：用药番茄完成一份专业CCI报告 Biogen公布Ⅱ期CELIA研究完整数据：Tau靶向ASO疗法Diranersen展现临床获益 药番茄追踪新药情报，分享AI在制药领域落地应用，欢迎感兴趣的朋友加群交流。 若如上二维码添加失败，也可以添加助理微信进群。 声明：本文内容供业内同行交流学习，不代表药番茄表平台立场，不构成任何投资意见和建议。药番茄不对任何主体因使用本文内容而导致的任何损失承担责任。内容如有疏漏，欢迎沟通指出！